Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem vs levofloxacin for infection prophylaxis during re-induction chemotherapy in pediatric intermediate/high-risk ALL
ChiCTR2400094209Phase 4Recruiting
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute lymphoblastic leukemia (ALL) comparing Faropenem group with Levofloxacin group (2 arms). Primary endpoint: Duration of agranulocytosis with fever. Started Dec 2024; status: recruiting.
02
Drugs
faropenemlevofloxacin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2400094209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094209.